Global Humanized Liver Mice Model Market Evaluated Over US $ 115 Million By 2029 End

  • 05 Jul 2019

Global humanized liver mice model market to value over USD 115 Million by 2029 end and register a CAGR of over 5.5% from 2019 to 2029.

Humanized mice models are mice that perform human functioning due to the presence of similar genes. Humanized mice models can be attained, through gene modification and replacement. 

Extensive research efforts are focused on developing efficient and new humanized liver mice models. Initially, using simple immune-deficient methods were employed, and mice were implanted with human liver cells or hepatic cancer cells. However, the results were not as desired and consistent. The unreliability of the process led to the discovery of immune-deficient mice that naturally annihilate the mice liver allowing the human liver cells to grow and replace to form stable humanized liver mice models. For instance, a number of studies are exploring the use of PPARalfa and AFC8-based mice models for the development of a humanized liver mice model. Another humanized liver mice model known as the hPXR/CAR/CYP3A4/ 2D6/2C9 mouse has 33 mouse genes replaced with human genetic counterparts. Furthermore, with the improvement in medical science and genetic technology, the scope of developing new genetically engineered humanized liver mice models has widened. The invention of CRISPR technology is one such instance.

The approval of numerous liver disease-associated drugs by the FDA  has also promoted the growth of the market and encouraged research and development. The high expenses of humanized liver mice are projected to restrain the growth of the market. For instance, the immune-deficient mice used for liver studies through grafting are available in the range of US$ 140–500, whereas chimeric humanized liver mice with 75–90% of human hepatocyte replacement, cost about US$ 2500–3500. In addition, since these are specifically genetically modified species, the shipping costs are also significantly higher along with the special containers and facility provided during the transportation, these overheads invariably increase the overheads. 

Replace, reduce and refine is the policy followed in animal studies. It provides a framework for humane research. Replacement of animal models allows the use of alternatives such as 2D & 3D cell lines and is recommended to reduce the number of animals. The aim behind this is to minimize animal suffering without compromising on the statistics of the experiment or research.

By Application
●    Pharmacokinetics Studies
●    In-vivo Liver Toxicity Testing
●    Drug Metabolism Studies
●    Others

By Model
●    uPA-SCID
●    FRG KO Mice
●    TK-NOG Mice
●    Other Models

By End User
●    Pharmaceutical Companies
●    Biotechnology Companies
●    Contract Research Organizations (CRO’s)
●    Academic & Research Institutes

By Region:
●    Europe  
●    North America  
●    APAC  
●    Latin America
●    Rest of World 
The market of North America garners the maximum revenue and is expected to grow at the highest CAGR during the forecast period. 

Competitive Landscape:  
●    Tier 1 players- established companies in the market with a major market share  
●    Tier 2 players 
●    Emerging players which are growing rapidly 
●    New Entrants  
Major market influencers include Yecuris Corporation, PhoenixBio Group, Beijing Vitalstar Biotechnology Co. Ltd., Hera BioLabs, Taconic Biosciences, Inc., University of Massachusetts Medical School, Oncodesign, University of Nebraska Medical Center and Jackson Laboratory.

FutureWise Key Takeaways  
●    Growth prospects 
●    SWOT analysis 
●    Key trends 
●    Key data points affecting market growth  

Objectives of the Study: 
●    To provide an exhaustive analysis on the humanized liver mice model based on application, model, end user and region    
●    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) 
●    To evaluate and forecast micro-markets and overall market  
●    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa 
●    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions 
●    Profiling of companies to evaluate their market shares, strategies, financials and core competencies


Get unlimited analyst support and customise this study further to your requirements, contact